Open For Enrollment

Protocol	Age Group	Key Criteria	PI & Location
YKP509C003: A Randomized, Double-blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Carisbamate (YKP509) as Adjunctive Treatment for Seizures Associated with Lennox-Gastaut Syndrome in Children and Adults, with Optional Open-Label Extension	4-55	• Documented Hx of LGS with first seizure <11 years of age • 1-4 AEDs with stable dose in past 30 days • At least 8 drop seizures with potential to fall during the 4 week baseline period • Cannot have status epilepticus within 12 weeks prior to visit 1.	1. Dr. Segal: Hackensack
XPF-010-303: A Randomized, Double-blind, Placebo-Controlled, Multicenter, Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures	>12	• Dx with PGTCS • 1-3 AED with stable dose in past 30 days • Must have 3 PGTCS during 8 week of screening period • Cannot have status epilepticus within 12 months prior to visit 1	1. Dr. Asfi Rafiuddin: Hackensack.
LP352-302: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter	2-65	• Dx of Dravet Syndrome • 4 Countable motor seizures per month in past 3 months prior to visit 1	1. Dr. Mahalingam: Morristown

Please Reach out to Research Team if you have any eligible Patients. Research Direct line: 551-497-5000.

Hardik Rana: hrana@epilepsygroup.com; Ryan Zahn: rzahn@epilepsygroup.com; Anbudoss Devapiriyam: adevapiriyam@epilepsygroup.com

Study to Investigate the Efficacy, Safety, and Tolerability of LP352 in the Treatment of Seizures in Children and Adults with Dravet Syndrome		• 1-4 ASMs with stable dose for 4 weeks prior to visit 1 • Cannot have Hx of hospitalization requiring mechanical ventilation due to status epilepticus within 3 months prior to visit 1	
LP352-301: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Investigate the Efficacy, Safety, and Tolerability of LP352 in the Treatment of Seizures in Children and Adults with Developmental and Epileptic Encephalopathies and Lennox Gestaut syndrome	2-65	• Dx Of DEE(other than LGS) with onset of seizure < 5 years of age • LGS with onset of seizure < 8 years of age • Countable motor seizures per month in past 3 months prior to visit 1 • 1-4 ASMs with stable dose for 4 weeks prior to visit 1 • Cannot have Hx of hospitalization requiring mechanical ventilation due to status epilepticus within 3 months prior to visit 1	1. Dr. Mahalingam: Morristown.

Please Reach out to Research Team if you have any eligible Patients. Research Direct line: 551-497-5000.
Hardik Rana: hrana@epilepsygroup.com; Ryan Zahn: rzahn@epilepsygroup.com; Anbudoss Devapiriyam: adevapiriyam@epilepsygroup.com

XPF-010-302: A Randomized, Double-Blind Placebo-controlled multicenter Phase 3 Study to Evaluate the safety tolerability and efficacy of XEN1101 as adjunctive Therapy in focal -onset Epilepsy	18-75	• DX with POS (Focal) • HX of only focal aware without motor seizures only will not be allowed • May be on 1 to 3 AEDS • During the 8-week baseline period must have more than 4 focal seizures within 28 days	1. Dr. Rafiuddin: Hackensack
XPF-010-304: A Multicenter, Open-label, Long-term, Safety, Tolerability, and Efficacy Study of XEN1101 in Adults Diagnosed with Epilepsy	18-75		1. Dr. Rafiuddin: Hackensack
CT-AMT-260-01: A Multi-center, Phase 1/2a, First-in-human (FIH) Study Investigating the Safety, Tolerability and Efficacy of AMT-260 in Adults with Unilateral Refractory Mesial Temporal Lobe Epilepsy (MTLE) Administered via Magnetic Resonance Imaging (MRI)-guided Convection-enhanced Delivery (CED)"	18-65	• Dx of Unilateral Refractory MTLE • Willingness to Undergo Surgical Procedure • Average of 2 documented focal seizures per 30-day period for past 3 months. Cannot have any implant that is nor MRI compatible.	1. Dr. Rafiuddin: Hackensack
BHV7000-302/BHV7000-303: A Phase 2/3 Multicenter, Randomized, Double-Blind,	18-65	• DX with POS (Focal) • HX of only focal aware without motor seizures	1. Dr. Rafiuddin: Hackensack

Please Reach out to Research Team if you have any eligible Patients. Research Direct line: 551-497-5000.
Hardik Rana: hrana@epilepsygroup.com; Ryan Zahn: rzahn@epilepsygroup.com; Anbudoss Devapiriyam: adevapiriyam@epilepsygroup.com

Placebo-Controlled, Study to Evaluate the Efficacy, Safety and Tolerability of BHV-7000 in Subjects with Refractory Focal Epilepsy		only will not be allowed • May be on 1 to 3 AEDS • During the 8-week baseline period must have more than 4 focal seizures within 28 days	
Supernus, 817P203: A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of SPN-817 in Adults with Focal Onset Seizures	18-70	1. Dx with POS(Focal) 2. At least 4 focal onset seizures in 4 weeks. 3. May be on 1 to Max. 4 ASMs.	1. Dr. Rafiuddin: Hackensack
RAD-GRIN-101: A Multinational, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effect on Seizures and Behavioral Symptoms of Radiprodilin Participants with GRIN-related Neurodevelopmental Disorder in an Open-Label, Phase 1b Cohort and Two Randomized, Double-blind Cohorts, followed by an Open-label Extension	1 month – 18 years	1. Dx with GRIN- NDD 2. At least 1 Countable motor seizure per week. 3. Must have failed 2 ASMs in the past 4. On stable dose of 1-4 ASMs. 5. Body weight > 5 kg.	1. Dr. Segal: Hackensack

Please Reach out to Research Team if you have any eligible Patients. Research Direct line: 551-497-5000.
Hardik Rana: hrana@epilepsygroup.com; Ryan Zahn: rzahn@epilepsygroup.com; Anbudoss Devapiriyam: adevapiriyam@epilepsygroup.com